Literature DB >> 1455401

The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase.

C Lenich1, R Pannell, J Henkin, V Gurewich.   

Abstract

We previously found that human pro-UK expressed in Escherichia coli is more active in fibrinolysis than recombinant human pro-UK obtained from mammalian cell culture media. To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK]. The latter two pro-UKs were obtained by expression of the human gene in a mammalian cell. The nonglycosylated pro-UKs were activated by plasmin more efficiently (approximately 2-fold) and were more active in clot lysis (1.5-fold) than the (+)pro-UK. Similarly, the nonglycosylated two-chain derivatives (UKs) were more active against plasminogen and were more rapidly inactivated by plasma inhibitors than the (+)UK. These findings indicate that glycosylation at Asn-302 influences the activity of pro-UK/UK and could be the major factor responsible for the enhanced activity of E. coli-derived pro-UK.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455401

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

3.  Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

Authors:  Erica Atkins; Stephanie Zamora; Britny J Candia; Amy Baca; Robert A Orlando
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.